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Abstract
Use of imaging flow cytometry to assess induced DNA damage via the cytokinesis block micronucleus 
(CBMN) assay has thus far been limited to radiation dosimetry in human lymphocytes using high 
end, ‘ImageStream X’ series imaging cytometers. Its potential to enumerate chemically induced 
DNA damage using in vitro cell lines remains unexplored. In the present manuscript, we investigate 
the more affordable FlowSight® imaging cytometry platform to assess in vitro micronucleus (MN) 
induction in the human lymphoblastoid TK6 and metabolically competent MCL-5 cells treated with 
Methyl Methane Sulfonate (MMS) (0–5 µg/ml), Carbendazim (0–1.6 µg/ml), and Benzo[a]Pyrene 
(B[a]P) (0–6.3 µg/ml) for a period of 1.5–2 cell-cycles. Cells were fixed, and nuclei and MN were 
stained using the fluorescent nuclear dye DRAQ5™. Image acquisition was carried out using a 20X 
objective on a FlowSight® imaging cytometer (Amnis, part of Merck Millipore) equipped with a 
488 nm laser. Populations of ∼20 000 brightfield cell images, alongside DRAQ5™ stained nuclei/
MN were rapidly collected (≤10 min). Single, in-focus cells suitable for scoring were then isolated 
using the IDEAS® software. An overlay of the brightfield cell outlines and the DRAQ5 nuclear 
fluorescence was used to facilitate scoring of mono-, bi-, tri-, and tetra-nucleated cells with or 
without MN events and in context of the cytoplasmic boundary of the parent cell.
To establish the potential of the FlowSight® platform, and to establish ‘ground truth’ cell classification 
for the supervised machine learning based scoring algorithm that represents the next stage of our 
project, the captured images were scored manually. Alongside, MN frequencies were also derived 
using the ‘gold standard’ light microscopy and manual scoring. A  minimum of 3000 bi-nucleated 
cells were assessed using both approaches. Using the benchmark dose approach, the comparability 
of genotoxic potency estimations for the different compounds and cell lines was assessed across 
the two scoring platforms as highly similar. This study therefore provides essential proof-of-concept 
that FlowSight® imaging cytometry is capable of reproducing the results of ‘gold standard’ manual 
scoring by light microscopy. We conclude that, with the right automated scoring algorithm, imaging 
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Introduction
The in vitro micronucleus (MN) assay is a gold-standard test used 
worldwide to assess substances’ ability to cause DNA damage and 
chromosomal aberration. MN formation resulting from either 
chromosomal breaks or chromosomal loss is used as a measure of 
induced DNA damage. The MN assay is mandated by regulatory 
authorities as a robust genetic toxicity screening tool (1,2). Scoring 
slides using light microscopy is the conventional approach to detect 
cell with MN, as the method is simple, economical and is currently 
considered the ‘gold standard’ for MN scoring (3). However, this 
method is also associated with being low throughput and biased by 
potential scorer-subjectivity and extensive scoring time (4,5). A var-
iety of automated MN scoring platforms have therefore been devel-
oped in an attempt to obtain high-content, high throughput MN 
scores with reduced subjectivity.
To date, most automated MN scoring approaches have employed 
automatic slide-scanning microscopy in conjunction with object-
based image classification or else have employed conventional flow 
cytometry (4,6,7). Commercially available automated microscopy 
platforms such as the Metafer™ (MetaSystems, Newton, USA) 
enable rapid MN scoring (8). However, lack of cytoplasmic staining, 
limitations of the current image analysis classifiers in the detection 
of overlapping nuclei/MN, the need for optimisation of the classifier 
setting for new chemicals, and the importance of high quality of slide 
preparations have been identified as issues with this platform (9,10). 
In contrast, fully automated flow cytometry based MN scoring plat-
forms provide an advantage over microscopy based approaches 
in terms of high-throughput, rapid assessment of MN events (11). 
However, the fact these approaches typically lyse cells and score the 
resultant, mixed population of nuclei and micronuclei has led to con-
cerns such as over-scoring of the MN events due to misclassification 
of apoptotic bodies/debris (12).
FlowSight® and ImageStream X MarkII® (Amnis, part of Merck 
Millipore) are examples of commercially available imaging flow cytom-
etry platforms. These instruments work much like traditional flow 
cytometers; but additionally, an image of each event or cell is acquired, 
providing additional information on the spatial location of any fluor-
escent stainings employed. Typically, these instruments are equipped 
with 3–6 lasers and permit up to 12 channels of fluorescence data to 
be acquired alongside brightfield and darkfield images, thus enabling 
the high-content analysis of cells in suspension. In this way, imaging 
flow cytometry platforms allow the capture of high resolution images 
of 10 000–20 000 cells within minutes. Using an ImageStream X flow 
cytometer Rodrigues et al. (13) have shown that imaging flow cytom-
etry can be used to effectively assess and score radiation induced MN in 
the cytokinesis blocked MN (CBMN) assay in primary human lympho-
cytes. However, the potential of the compact, more transportable and 
affordable FlowSight® imaging flow cytometer for scoring chemically 
induced MN in vitro in the CBMN and MN assay remains unexplored. 
To this end, here we evaluate the FlowSight® platform for the assess-
ment of in vitro MN following cytokinesis block in the human lympho-
blastoid cell lines TK6 and MCL-5 treated with known DNA damaging 
chemicals. These two P53 competent human lymphoblastoid cell lines 
were chosen on the basis that the TK6 cells are widely employed choice 
of cell line in both industry and academia due to their noted suitabil-
ity in the OECD test guideline for the in vitro micronucleus assay (1). 
Similarly, the MCL-5 cell line is also frequently employed due to its sta-
ble expression of active cytochrome P450 metabolic enzymes that are 
vital for the activation of certain test articles (14). Manually scored MN 
frequencies derived from the images captured using FlowSight® are 
compared to the MN scores obtained from light microscopy to directly 
assess the reproducibility of the results from the two approaches. Our 
findings therefore represent an important first step towards the devel-
opment of a high-throughput imaging flow cytometry based approach 
to compound screening for induced DNA damage via the MN assay 




Methyl Methane Sulfonate (CAS no.  12925), Carbendazim (CAS 
no.  10605-21-7) and Benzo[a]pyrene (B[a]P) (CAS no.  50-32-8) 
were purchased from Sigma Aldrich, UK.
Cell lines and treatment
Human lymphoblastoid TK6 and MCL-5 cells were obtained from 
American Type Culture Collection (ATCC), Manassas, VA, USA. 
TK6 cells were cultured in RPMI 1640 media (Gibco, Paisley, UK), 
supplemented with 1% Pen/Strep (100 U/mL Penicillin and 100 μg/
mL Streptomycin) and 10% heat inactivated horse serum (Gibco, 
Paisley, UK). MCL-5 cells were culture in RPMI 1640 (Gibco, Paisley, 
UK), supplemented with 10% horse serum, 1% L-glutamine (Gibco, 
Paisley, UK) and hygromycine-B. Cells were seeded at 2 × 105 cells in 
25 cm2 flask (Fisher brand), incubated at 37°C for 1.5–2 cell- cycles 
in the presence of MMS, Carbendazim and B[a]P.
Cytotoxicity and cytostasis
Relative Population Doubling (RPD) was used to estimate the high-
est dose to be included based on cytotoxicity. The 50 ± 5% reduction 
in percentage RPD was used to estimate highest tested concentra-
tion in accordance with the recommendation of the Organisation 
for Economic Co-operation and Development (1). Cell counts were 
determined automatically using a Coulter counter (Beckman Coulter 
Inc.). The %RPD calculations were made as follows:
 %RPD Number of population doubling in treated cultures 1= ´ 00
Number of population doubling in the vehicle control
Population Doubling (PD) was calculated as follows:
 
PD  log 
cell count after treatment










Cytokinesis Block Micronucleus (CBMN) assay
The in vitro CBMN assay was used to study MN induction in both 
TK6 and MCL-5 cells treated with MMS, Carbendazim and B[a]P. 
Cells were incubated with 3–6 µg/ml Cytochalasin-B (Cyto-B) con-
tinuously for a period of 30 h. Following incubation, cells were har-
vested via centrifugation at 200×g for 10 min. The supernatant was 
aspirated and the pellet was re-suspended in 10 ml phosphate-buff-
ered saline (PBS) (Gibco®). The samples were then fixed and stained 
for MN scoring using imaging flow cytometry and manual scoring.
The light microscopy manual scoring approach 
(gold standard)
In the case of manual scoring conducted by light microscopy, 100 µl 
of cell suspension was centrifuged (Cytospin™ centrifuge) onto pol-
ished glass slides, fixed in 90% ice cold methanol for 10  min and 
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air dried at room temperature. Air dried slides were stained in 4% 
Giemsa solution (VWR International Ltd., Poole, UK) at room tem-
perature. Giemsa stained slides were washed in Gurr buffer (Thermo 
Fisher Scientific) (pH 6.8), air dried and a cover slip was mounted on 
these slides using DPX mounting solution. The MN scoring was car-
ried out using a 100× magnification objective on a light microscope 
(Olympus BX 51). Cells with two circular nuclei, non-overlapping, 
evenly stained and confined within the cytoplasmic boundary of the 
cell were scored as bi-nucleated cells. MN that were circular/oval, 1/3-
1/16 the size of main nuclei and not overlapping the main nucleus of 
the bi-nucleated cells were included in the overall MN scores (15). The 
MN frequency per dose was obtained by manually assessing a total of 
3000 bi-nucleated cells obtained across three experimental replicates.
FlowSight® analysis
For the imaging flow cytometric analyses, post 1.5–2 cell-cycle 
treatment, the PBS was removed and the cells were fixed using 
BD FACS™ lysis solution (CAS- 349202). Two millilitres of the 
fixative was added to each pellet followed by 12 min incubation 
at room temperature. Fixed cells were then washed, centrifuged 
at 200×g for 10 min before discarding the supernatant and pro-
cessing for staining. Nuclei and MN were stained using 0.05 mM 
DRAQ5™ (CAS-564902, BD Biosciences) and were incubated 
for 30 min at room temperature prior to image acquisition using 
FlowSight®.
A 488 nm laser on FlowSight® (Amnis, part of EMD Millipore) 
was used to excite the DRAQ5 stained cells and images were cap-
tured automatically using the preinstalled INSPIRE®3.0 software. 
For image acquisition, 80  µl of cell suspension was processed on 
FlowSight®, with brightfield images captured alongside DRAQ5 
fluorescence images of nuclei and MN via the 20× objective. The 
bright field image Aspect Ratio and Area parameters of the cells were 
then used to gate out debris and dead cells and to isolate the sin-
gle cell population. Subsequently, cells acceptably within focus were 
further isolated by line scan gradient feature (brightfield gradient 
RMS). A total of 20 000 images of single, in-focus were captured on 
FlowSight® per dose/experimental replicate.
Prior to MN scoring, raw image files (.rif) obtained using 
INSPIRE® version 3.0 software were converted to Compensated 
Image Files (.cif) and Data Analysis Files (.daf) using identical set-
tings via batch processing with template file in the manufacturer’s 
IDEAS software (v5.0). An overlay of DRAQ5 fluorescence with the 
brightfield was then used for scoring and to assess that MN events 
lay within the cytoplasmic boundary of the parent cell. These over-
laid composite images were then manually scored to classify cells 
based on their morphology as mono-, bi- or tri-nucleates with and 
without micronuclei. A total of 3000 bi-nucleated cells with two cir-
cular nuclei, displaying similar DRAQ5 staining characteristics and 
non-compromised cytoplasmic membrane were scored to evaluate 
the MN frequency. MN scoring within the bi-nucleated cells was 
carried out by adopting the criteria designed for slide based scoring 
(15). Only MN that were labelled with DRAQ5, were circular/oval, 
1/3-1/16 the size of main nuclei of the bi-nucleated cells and were 
within the cytoplasmic boundary of the parent bi-nucleated cells 
were included in the final MN scores.
Statistical analysis
As necessary, data were log10 transformed to achieve a normal distri-
bution (assessed via the Shapiro-Wilk Normality Test) with the homo-
geneity of within-dose variance further assessed by Bartlett Test. The 
Bonferroni test for outlier’s was also conducted. If the transformed 
data passed these trend tests then the 1-sided Dunnett’s test was used 
to identify the no- and the lowest-observed genotoxic effect levels 
(NOGEL and LOGEL, respectively). Where the data failed these trend 
tests, then the 1-sided Dunn’s test was used to assess response signifi-
cance relative to control according to the guidance laid out in (16).
Benchmark dose (BMD) analysis was carried out using ‘defined’ 
as covariate, with ‘study’ by which compound, scoring platform and 
cell line were used. PROAST software version 63.3 was used, and the 
data were fitted using both the exponential and Hill nested model 
families that are recommended by the European Food Safety Agency 
for the analysis of continuous toxicological dose-response data (17). 
PROAST uses the likelihood ratio test to assess whether inclusion of 
additional model parameters results in a significant improvement in 
model fit. Increasingly complex models with more parameters were 
only accepted if the difference in the log-likelihood exceeded P < 0.05. 
This permitted the establishment of which model parameters could be 
considered constant across subgroups in the combined datasets. As 
in earlier work, it was assumed that the shape parameters for max-
imum response (parameter c) and log steepness (parameter d) were 
constant in each analysis, while parameters for background response 
(parameter a), potency (parameter b) and var (i.e. within-group vari-
ation were examined for covariate dependency. (18,19). Using this 
approach, BMD lower and upper 90% confidence intervals (BMDL 
and BMDU) were defined and plotted to provide a quantitative, visu-
ally intuitive potency ranking for chemicals (20). A critical effect size 
(CES; also known as benchmark response, BMR) of 10% was used in 
all presented analyses (21).
Results
Here, we set out to investigate whether FlowSight® is a viable plat-
form for the detection of chemically induced MN events in vitro using 
the human lymphoblastoid cell lines TK6 and MCL-5. Figure 1 clearly 
shows that with the FlowSight® platform, scorable, mono-nucleated, 
bi-nucleated, tri-nucleated and tetra-nucleated cells with or without 
MN can be captured accurately, without the need to lyse cells for MN 
assessment as is typically a requirement with conventional flow cytom-
etry based approaches. Overall, confidence in MN scoring is vastly 
improved by being able to easily visualise every cell collected. The cre-
ation of an overlay of bright field/DRAQ5 images is extremely useful, as 
this helps to eliminate the subjectivity issues that arise with MN scoring 
with platforms where MN identification is conducted in the absence of 
cytoplasmic stain (e.g. is the parent cell a true bi-nucleate? Does the MN 
event truly correspond to the cell being scored or to its neighbour? etc.). 
Furthermore, visual inspection of the composite images enables the user 
to differentiate true MN events from equivocal/false positive events (e.g. 
difference in staining intensity of MN and the parent nuclei and size 
based differences between tri-nucleated cells and MN).
FlowSight® derived MN scores are comparable to 
the ‘gold standard’ light microscopy approach
The background levels of MN induction (i.e. in the zero dose con-
trols) detected in the CBMN assay using FlowSight® were found 
comparable to manual MN frequencies using light microscopy based 
scoring, irrespective of the cell lines under investigation (Figure 2). 
Furthermore, the mean MN responses were comparable across the 
scoring platforms in TK6 cells for both MMS and Carbendazim 
treatment (Figure 2A/B). In the cells treated with MMS, both sys-
tems detected a significant (P < 0.05) increase in MN induction in 
response to 1.25, 2.5 and 5 μg/ml doses after 1.5–2 cell-cycle treat-
ment. Both platforms also identified a significant (P < 0.05) increase 
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Figure  2. Comparison of the MN responses manually scored using images collected by FlowSight® imaging cytometry (black) and by conventional light 
microscope based manual scoring (white) in TK6 cells treated with MMS (A) and Carbendazim (B) following 1.5–2 cell-cycle treatment. (* indicates a significant 
increase in the MN formation over the control (P < 0.05)). Error bars represent mean ± SD (n = 3).
Figure 1. Example of cell images captured by FlowSight® imaging cytometry and manually classified as mono-nucleated, bi-nucleated, tri-nucleated and tetra-
nucleated cells with or without MN. The left-most panel denotes cell classification, then moving right-wards, brightfield images, nuclear fluorescence (DRAQ5) 
and composite image overlay (brightfield/DRAQ5) are shown. MN events are highlighted by the yellow circles.
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in MN for 0.8, 1 and 1.6 μg/ml Carbendazim doses following similar 
treatment regime. Again, the FlowSight® MN frequencies were in 
excellent concordance with the MN responses observed using con-
ventional manual scoring by light microscopy.
Both MN scoring platforms also detected a significant (P < 0.05) 
increase in MN induction using the metabolically competent (i.e. 
expressing five cDNA that encode metabolic activating enzymes) (14) 
MCL-5 cells following 1.5–2 cell-cycle treatment (Figure 3). A sig-
nificant (P < 0.05) increase in the MN induction was also observed 
in response to the 6.3 µg/ml dose of B[a]P using FlowSight®. Both 
the 0.75 and 6.3 µg/ml B[a]P concentrations were identified to cause 
a significant (P < 0.05) increase in MN when scored by traditional 
light microscopy.
Each of the analyses presented in Figure 3–4 indicated that the 
manually derived FlowSight® MN scores were in excellent con-
cordance with those obtained in the comparative, manually scored 
light microscopy studies. To assess the different compound’s potency 
ranking, as well as the degree of concordance across the techniques 
quantitatively, the BMD10 was calculated from the dose-response 
data for each study (i.e. chemicals, cell line and scoring method) 
using both the Hill and exponential model families (Figure 4). In each 
instance, the plotted BMD confidence intervals showed considerable 
overlap between scoring methods for each chemical, indicating good 
concordance across the FlowSight® and conventional light micros-
copy scoring techniques. The non-overlapping confidence intervals 
established between chemicals also allowed a potency ranking to 
be established from the data in order of potency of: Carbendazim 
(TK6)>MMS (TK6)≥B[a]P (MCL-5) (20).
Discussion and Conclusion
The proof-of-concept data provided here shows that the imaging 
flow cytometry based CBMN assay has the potential to be used 
to assess the genotoxicity of chemical compounds in immortalised 
human cell lines in addition to monitoring MN events in periph-
eral blood mononuclear cells for radiation dosimetry purposes as 
shown previously (13). We also show that the derived dose-response 
data were in excellent concordance across the imaging cytometry 
and light microscopy platforms. Here, the BMD approach was used 
to compare data from the two scoring methods as there is a grow-
ing consensus that this method constitutes a robust approach for 
comparing potency estimates arising across different covariates (e.g. 
compounds, cell lines, time points etc.) (19,20). Recently, the com-
bined BMD-covariate approach has similarly been used to assess the 
comparability of potency estimates arising across different variants 
(e.g. employing different rodent species and/or different reporter 
transgenes) of the transgenic rodent gene mutation test (23). The 
approach has also been used to compare compound potency esti-
mates arising from data collected by different laboratoreis during the 
Japanese in vivo ring trial for the Pig-a gene mutation assay and the 
transgenic mutation system (22).
Here, FlowSight® (imaging flow cytometry) based MN scoring 
was carried out in unlysed cells, giving it an advantage over stand-
ard flow cytometric platforms that often require cell lysis for MN 
assessment. The strategy to assess MN induction in the absence of 
cell lysis adheres to OECD recommendations, whereby MN scoring 
should ideally be conducted in cells with intact cytoplasmic mem-
branes (12). Moreover, visual inspection of the cellular images helps 
to reject apoptotic cells and permits correct identification of bi-, 
tri- and multi-nucleated cells with and without MN, which other-
wise are suspected to influence MN scoring upon lysis with the 
conventional flow cytometric method (3). Standard flow cytometry 
based MN scoring is also limited to mono-nucleated cells, whereas 
the approach described here is suitable for MN scoring both with 
or without cytokinesis block, with many laboratories favouring 
one approach over the other. In addition to this, the FlowSight® 
approach allows every cell and MN event to be visualised and 
recorded automatically during the data acquisition process. When 
compared to manual scoring using light microscopy, FlowSight® 
image-sets of 20 000 cells can be acquired within minutes, providing 
statistically relevant populations of cells for downstream analysis. 
The images can be archived, accessed, could be quickly re-scored as 
better-trained automated algorithms become available and can be 
submitted to regulatory authorities or scientific journals to validate 
findings as required.
During the current project, we used the FlowSight® imaging 
cytometer (Amnis, part of Merck Millipore) and captured images 
using the standard-equipped 20× objective. The image resolution 
could be further improved by using a higher magnification objective 
(e.g. 40× objective). However, the 20X objective proved effective in 
the initial proof-of- concept work presented here. The FlowSight® 
imaging cytometer was also of interest to us as previous work has 
used the more expensive ‘ImageStreamXʼ series imaging cytometers. 
The FlowSight® model is designed to be more compact and afford-
able and thus our successes here are important, as the FlowSight® 
is more within reach of a wider range of research and industrial 
laboratories.
It is important to note that the speed and objectivity of MN scoring 
could be further enhanced through the development of a fully auto-
mated algorithm for MN scoring. We propose that supervised machine 
learning is the ideal approach for such image analysis based classifi-
cations, and we are working towards such an approach at the cur-
rent time, using the manually classified events established here as the 
‘ground truth’ to train and validate the algorithm. A further advantage 
of using such an approach in comparison to the traditional object-
based classifiers used to-date is that accuracy can be improved each 
time new data sets are available for analysis. This approach also has 
the potential to be more flexible in detecting events that are chemical 
specific, for example, some current classifiers only score cells with per-
fectly circular nuclei, whereas aneugen exposure can increase the num-
ber of cells with non-circular nuclei that are none-the-less still scorable 
(3). Furthermore, there is also the potential to introduce additional 
Figure 3. Comparison of the MN responses manually scored using images 
collected by FlowSight® (black) and light microscope based manual scoring 
(white) in MCL-5 cells treated with B[a]P for 1.5–2 cell cycles. (* indicates a 
significant increase in the MN formation over the control (P < 0.05)). Error 
bars represent mean ± SD (n = 3).
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markers (e.g. antibody labels) to provide additional information on the 
mechanism for MN induction as clastogenic or aneugenic (e.g. γH2AX 
or phosphorylated histone H3) (23,24).
We suggest that an inter-laboratory trial is essential to test the 
reproducibility and transferability of the experimental protocol, and 
once fully developed the automated machine learning based MN scor-
ing algorithm as well. We are moving forward with both of these goals 
in mind, but this initial paper focusses on providing proof-of-concept 
that chemically induced MN events can be captured and scored using 
FlowSight®, in different cell lines, following exposure to aneugens and 
clastogens, and that the events recorded by imaging flow cytometry 
align with manual scores recorded by gold standard light microscopy. 
This proof-of-concept has been realised, and the supervised machine 
learning approach based on our developing ground truth will now be 
fully developed and validated using various cell lines and test articles 
with varying modes-of-action via inter-laboratory trial.
Supplementary data
Supplementary Figures  S1 and S2 are available at Mutagenesis 
Online.
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